WASHINGTON (January 29, 2026) — The Board of Directors of the Association for Accessible Medicines has elected Bob Hoffman as Chair. Hoffman, Chief Commercial Officer of U.S. Generics for Lupin Pharmaceuticals, Inc. most recently served as Vice Chair of the AAM Board for the past two terms. Also elected as board officers, Punit Patel, President and CEO, Americas, Zydus Group as AAM Vice Chair, and Jeff Burd, President & CEO, North America, Ajanta Pharma USA Inc., who was reelected to a third term as Treasurer.
“It is an honor to serve as AAM board chair and I thank the board for the privilege,” said Bob Hoffman, Chair of the AAM Board of Directors. “On behalf of the board, we are grateful to Keren Haruvi for her service as chair and for her hard work and tireless advocacy for our industry and the patients we serve. We will continue to work as a board and with AAM staff to protect and expand patient access to generic and biosimilar medicines, shine a light on opaque business practices getting in the way of lower-cost medicines, and continue to work with leaders across the country to empower a truly sustainable supply chain and competitive market for critical lifesaving medicines.”
Hoffman has over 33 years of experience in the pharmaceutical industry. Prior to establishing Lupin’s generic business in the U.S., he held management positions at Schein Pharmaceuticals, Takeda Pharmaceuticals, Lek Pharmaceuticals, and Pliva Pharmaceuticals.
John Murphy III, President and CEO of AAM, stated, “AAM is fortunate to have stability and continuity in our board leadership and we look forward to working with Bob and the entire board to advance our industry’s mission to providing safe, effective, and more affordable medicines to American patients. We will continue to push for reforms to remove regulatory barriers, stop patent abuses and dubious PBM practices, and increase overall sustainability and resiliency for generic and biosimilar medicines.”
MEDIA CONTACT:
For media inquiries, contact the Communications Department at media@accessiblemeds.org.
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 12 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at biosimilarscouncil.org.
